1. Home
  2. AIRJW vs LYEL Comparison

AIRJW vs LYEL Comparison

Compare AIRJW & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AIRJW

Montana Technologies Corporation Warrant

N/A

Current Price

$0.95

Market Cap

0.0

Sector

Finance

ML Signal

N/A

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$11.02

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRJW
LYEL
Founded
N/A
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
320.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
AIRJW
LYEL
Price
$0.95
$11.02
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
8.8K
88.6K
Earning Date
03-21-2025
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.46
$10.46
52 Week High
$1.87
$45.00

Technical Indicators

Market Signals
Indicator
AIRJW
LYEL
Relative Strength Index (RSI) 36.11 27.52
Support Level $0.63 N/A
Resistance Level $1.07 $15.38
Average True Range (ATR) 0.06 0.77
MACD -0.04 -0.39
Stochastic Oscillator 2.73 2.56

Price Performance

Historical Comparison
AIRJW
LYEL

About AIRJW Montana Technologies Corporation Warrant

AirJoule Technologies Corp is an advance technology company whose purpose is to free the world from its water and energy constraints by delivering groundbreaking sorption technologies. The company platform technology, AirJoule, produces pure distilled water from air and, at commercial scale, will mitigate water scarcity through distributed water generation for businesses and consumers around the world. Its products are especially valuable for industrial users, which generate amounts of waste heat that can be used to power sorption technologies to produce low-cost pure distilled water and dehumidified air, two key inputs for a variety of industrial activities, including data centers and advance manufacturing. The Company operates as a single operating and reportable segment.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: